Developer docs
API playgroundTry for free, no card

Search company profiles

Cytyc

Full company profile

uuid0009wcc

Namestring
Cytyc
Legal namestring
Cytyc
Websiteurl
cytyc.com
Company typeenum
Private
Founded yearint
1987
Descriptiontext

Cytyc was a developer, manufacturer, and supplier of diagnostic and surgical products and medical imaging systems focused on women's health. Its portfolio spanned the detection, diagnosis, and treatment of conditions across the women's health lifecycle, including cervical cancer screening (notably the ThinPrep cytology platform), minimally invasive gynecological surgery, breast health diagnostics, and related molecular diagnostic and therapeutic technologies. The company served women's healthcare providers — hospitals, clinical laboratories, and physician practices — as its primary customer segment, distributing products through a combination of direct sales and dealer networks.

Pre-Hologic, Cytyc pursued an aggressive inorganic growth strategy, completing at least six disclosed acquisitions between 2001 and 2007: Pro-Duct Health (2001, $167.5M), Digene Corporation (2002, $553.7M), Novacept (2004, $325M), Proxima Therapeutics (2005, $160M), Adeza Biomedical (2007, undisclosed), and Adiana (2007, $215M). These moves broadened Cytyc across molecular diagnostics, gynecological surgical devices, and prenatal diagnostics, transforming it from a single-product cytology company into a diversified women's health platform. In 2007, Cytyc was itself acquired by Hologic, becoming the anchor asset in Hologic's women's health franchise. Today, Cytyc no longer operates as an independent reporting entity; its products, IP, and customer relationships are integrated into Hologic, which sells across 36 countries via direct sales, dealer networks, and the iStore e-commerce platform. Cytyc's pre-acquisition ownership structure, founding investors, and standalone capital structure are not documented in available sources.

Short descriptiontext

Cytyc developed, manufactured, and supplied diagnostic, surgical, and medical imaging products for women's healthcare providers. Acquired by Hologic in 2007; its cytology, diagnostics, and surgical franchises now operate inside Hologic's global women's health platform.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersMarlborough, United States
HQ citystring
Marlborough
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
women's health diagnostics, medical imaging systems, cytology testing, surgical diagnostics products, molecular diagnostics devices
Industry3 codes
PRIMARYHLAKAJAD
Gynecologic Oncology
SECONDARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKAJAL
Gynecology (General Non-Obstetric Care)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Women's Health Diagnostics
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cytyc was a developer, manufacturer and supplier of diagnostic and surgical products and medical imaging systems for women's health. Its portfolio spanned cytology, molecular diagnostics, breast health, gynecological health and related screening technologies sold primarily to women's healthcare providers and clinical laboratories. Following its 2007 acquisition, the Cytyc product lines were integrated into Hologic's broader women's health diagnostics and imaging portfolio.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product and services information for Cytyc was found in the provided sources. The source material contains information about Hologic (which acquired Cytyc in 2007) and general women's health industry news, but no specific Cytyc-branded products, modules, or service offerings were documented in the scraped content.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hologic acquired Cytyc as part of its strategic expansion in women's health diagnostics. Hologic has completed 22 acquisitions totaling $14.16 billion in the women's health sector, making it the most active strategic acquirer with repeat acquisition behavior reinforcing women's health as a priority growth area.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Cytyc's parent company and the largest women's health diagnostics incumbent. Hologic now operates Cytyc's ThinPrep, HPV, NovaSure, and breast imaging product lines within its diagnostics and surgical franchises, making it the most directly comparable player across Cytyc's full portfolio.

TypeBroad incumbent
Description

BD is a global medical device and diagnostics company with women's health and cervical cancer screening offerings, including molecular diagnostics and collection devices. Comparable to Cytyc as a broad incumbent across diagnostics and surgical instruments.

TypeDirect peer
Description

Qiagen offers the digene HPV Test and broader molecular diagnostics for women's health screening, directly competing with Cytyc's HPV testing franchise inherited via the Digene acquisition. Both compete in HPV and cervical cancer molecular diagnostics.

TypeBroad incumbent
Description

Roche is a global diagnostics leader offering the cobas HPV test and broader cervical cancer screening solutions. It directly competes with Cytyc's ThinPrep/HPV franchise while also serving adjacent IVD markets.

TypeDirect peer
Description

CooperSurgical is a women's health medical device company with products in reproductive medicine, gynecology, and fertility, including minimally invasive surgical solutions. Comparable to Cytyc's NovaSure endometrial ablation and surgical women's health portfolio.

TypeDirect peer
Description

Myriad Genetics provides molecular diagnostic tests for hereditary cancer risk, including breast and gynecologic cancers. It overlaps with Cytyc's women's health diagnostics focus on cancer risk assessment and screening.

TypeEmerging player
Description

Natera offers reproductive and women's health genetic testing, including non-invasive prenatal screening and hereditary cancer tests. Comparable to Cytyc's women's health diagnostics franchise, though with a more focused genetic testing orientation.

TypeBroad incumbent
Description

Carestream provides medical imaging systems and healthcare IT solutions used across women's health applications. Comparable to the medical imaging portion of Cytyc's product portfolio.

TypeBroad incumbent
Description

Philips is a global medical imaging leader offering mammography and women's health imaging systems. Comparable to Cytyc's breast imaging product line as a broad imaging incumbent.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott is a global diagnostics and medical device company with women's health offerings across immunoassays, molecular diagnostics, and point-of-care testing. Comparable to Cytyc as a broad IVD incumbent with women's health exposure.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cytyc

Women's Health Diagnosticscytyc.com

Cytyc developed, manufactured, and supplied diagnostic, surgical, and medical imaging products for women's healthcare providers. Acquired by Hologic in 2007; its cytology, diagnostics, and surgical franchises now operate inside Hologic's global women's health platform.

What Cytyc does

Cytyc was a developer, manufacturer, and supplier of diagnostic and surgical products and medical imaging systems focused on women's health. Its portfolio spanned the detection, diagnosis, and treatment of conditions across the women's health lifecycle, including cervical cancer screening (notably the ThinPrep cytology platform), minimally invasive gynecological surgery, breast health diagnostics, and related molecular diagnostic and therapeutic technologies. The company served women's healthcare providers — hospitals, clinical laboratories, and physician practices — as its primary customer segment, distributing products through a combination of direct sales and dealer networks.

Pre-Hologic, Cytyc pursued an aggressive inorganic growth strategy, completing at least six disclosed acquisitions between 2001 and 2007: Pro-Duct Health (2001, $167.5M), Digene Corporation (2002, $553.7M), Novacept (2004, $325M), Proxima Therapeutics (2005, $160M), Adeza Biomedical (2007, undisclosed), and Adiana (2007, $215M). These moves broadened Cytyc across molecular diagnostics, gynecological surgical devices, and prenatal diagnostics, transforming it from a single-product cytology company into a diversified women's health platform. In 2007, Cytyc was itself acquired by Hologic, becoming the anchor asset in Hologic's women's health franchise. Today, Cytyc no longer operates as an independent reporting entity; its products, IP, and customer relationships are integrated into Hologic, which sells across 36 countries via direct sales, dealer networks, and the iStore e-commerce platform. Cytyc's pre-acquisition ownership structure, founding investors, and standalone capital structure are not documented in available sources.

Cytyc firmographics

Firmographics
Name
Cytyc
Legal name
Cytyc
Website
https://cytyc.com
Company type
Private
Founded year
1987
Operating status
Acquired
Headcount range
5,001–10,000 employees
Short description
Cytyc developed, manufactured, and supplied diagnostic, surgical, and medical imaging products for women's healthcare providers. Acquired by Hologic in 2007; its cytology, diagnostics, and surgical franchises now operate inside Hologic's global women's health platform.
Ownership category
akta.pro rank

Cytyc industry classification

Industry
Product category
Women's Health Diagnostics
NAICS
Surgical Appliance and Supplies Manufacturing (339113), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAKAJAD
Gynecologic Oncology
SECONDARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKAJAL
Gynecology (General Non-Obstetric Care)

Keywords

  • Women's health diagnostics
  • Medical imaging systems
  • Cytology testing
  • Surgical diagnostics products
  • Molecular diagnostics devices

Where Cytyc is headquartered

Location

Headquarters

HQ city
Marlborough
HQ country
United States
HQ region
North America

Markets served

Cytyc business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Distribution channels2 records

Marketing channels3 records

Cytyc product offering

Product offering

Core offering

Cytyc was a developer, manufacturer and supplier of diagnostic and surgical products and medical imaging systems for women's health. Its portfolio spanned cytology, molecular diagnostics, breast health, gynecological health and related screening technologies sold primarily to women's healthcare providers and clinical laboratories. Following its 2007 acquisition, the Cytyc product lines were integrated into Hologic's broader women's health diagnostics and imaging portfolio.

Product overview

No product and services information for Cytyc was found in the provided sources. The source material contains information about Hologic (which acquired Cytyc in 2007) and general women's health industry news, but no specific Cytyc-branded products, modules, or service offerings were documented in the scraped content.

Differentiator

Problem solved

Functional benefit

Companies that use Cytyc

Customer profile

Segments1 record

Ideal customer profiles1 record

Cytyc technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cytyc partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • HologiccoreStrategic or Co-development PartnerHologic acquired Cytyc as part of its strategic expansion in women's health diagnostics. Hologic has completed 22 acquisitions totaling $14.16 billion in the women's health sector, making it the most active strategic acquirer with repeat acquisition behavior reinforcing women's health as a priority growth area.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Cytyc competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Cytyc's parent company and the largest women's health diagnostics incumbent. Hologic now operates Cytyc's ThinPrep, HPV, NovaSure, and breast imaging product lines within its diagnostics and surgical franchises, making it the most directly comparable player across Cytyc's full portfolio.
  • Becton Dickinson (BD): BD is a global medical device and diagnostics company with women's health and cervical cancer screening offerings, including molecular diagnostics and collection devices. Comparable to Cytyc as a broad incumbent across diagnostics and surgical instruments.
  • Roche Diagnostics: Roche is a global diagnostics leader offering the cobas HPV test and broader cervical cancer screening solutions. It directly competes with Cytyc's ThinPrep/HPV franchise while also serving adjacent IVD markets.
  • Carestream Health: Carestream provides medical imaging systems and healthcare IT solutions used across women's health applications. Comparable to the medical imaging portion of Cytyc's product portfolio.
  • Philips Healthcare: Philips is a global medical imaging leader offering mammography and women's health imaging systems. Comparable to Cytyc's breast imaging product line as a broad imaging incumbent.
  • Abbott Diagnostics: Abbott is a global diagnostics and medical device company with women's health offerings across immunoassays, molecular diagnostics, and point-of-care testing. Comparable to Cytyc as a broad IVD incumbent with women's health exposure.

Direct peers

  • Qiagen: Qiagen offers the digene HPV Test and broader molecular diagnostics for women's health screening, directly competing with Cytyc's HPV testing franchise inherited via the Digene acquisition. Both compete in HPV and cervical cancer molecular diagnostics.
  • CooperSurgical: CooperSurgical is a women's health medical device company with products in reproductive medicine, gynecology, and fertility, including minimally invasive surgical solutions. Comparable to Cytyc's NovaSure endometrial ablation and surgical women's health portfolio.
  • Myriad Genetics: Myriad Genetics provides molecular diagnostic tests for hereditary cancer risk, including breast and gynecologic cancers. It overlaps with Cytyc's women's health diagnostics focus on cancer risk assessment and screening.

Emerging players

  • Natera: Natera offers reproductive and women's health genetic testing, including non-invasive prenatal screening and hereditary cancer tests. Comparable to Cytyc's women's health diagnostics franchise, though with a more focused genetic testing orientation.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

Cytyc social profiles

Digital presence

Cytyc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cytyc leadership team

Management profile

Number of profiles

Profiles1 record

Cytyc funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cytyc M&A and investment

M&A and investment

M&A6 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytyc

What does Cytyc do?

Cytyc was a developer, manufacturer and supplier of diagnostic and surgical products and medical imaging systems for women's health. Its portfolio spanned cytology, molecular diagnostics, breast health, gynecological health and related screening technologies sold primarily to women's healthcare providers and clinical laboratories. Following its 2007 acquisition, the Cytyc product lines were integrated into Hologic's broader women's health diagnostics and imaging portfolio.

Is Cytyc a public or private company?

Cytyc is a private company. It is classified as corporate owned and is currently acquired.

When was Cytyc founded?

Cytyc was founded in 1987. It employs 5,001 to 10,000 people.

Where is Cytyc based?

Cytyc is headquartered in Marlborough, United States, in the North America region.

Who are Cytyc's main competitors?

Broad incumbents on record are Hologic, Becton Dickinson (BD), Roche Diagnostics, Carestream Health, Philips Healthcare and Abbott Diagnostics. Direct peers are Qiagen, CooperSurgical and Myriad Genetics. Natera is listed as an emerging player.

Does Cytyc have an API?

No public API is recorded for Cytyc.

What industry is Cytyc in?

Cytyc's product category is Women's Health Diagnostics. Its primary akta.pro industry code is HLAKAJAD, Gynecologic Oncology, with a secondary code of HLAHABAF, Mammography & Breast Imaging Systems. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireKalohexis Appoints Thomas Forest Farb-Horch to Board of DirectorsKalohexis appointed Thomas Forest Farb-Horch to its Board of Directors, where he will chair the Audit Committee. He brings over three decades of experience in life sciences and AI, including roles at Indevus, Interneuron, and Cytyc. The appointment aims to support Kalohexis's clinical programs and growth.HomepageNew Report Finds $100 Billion in Women’s Health Exits Over 25 Years, Challenging “Emerging Market” NarrativeAOA Dx released a comprehensive analysis tracking 276 women’s health company exits from 2000 to 2024, identifying over $100 billion in total exit value and 27 billion-dollar transactions, with 2024 alone reaching a record $21.4 billion. The report found that strategic acquirers accounted for 91% of exits, with repeat buyers including Hologic (22 acquisitions, $14.16 billion total deal value), CooperSurgical (21 acquisitions, $4.5 billion), Labcorp, Roche, Medtronic, and Allergan. Major exits cited include Hologic’s $18.3 billion take-private in 2025, Cytyc’s $6.2 billion acquisition by Hologic in 2007, Alere’s $5.3 billion acquisition by Abbott in 2017, and BillionToOne’s $4.4 billion IPO in 2025.Northeastern Global NewsAfter taking big risks, health care CEO Daniel Levangie persevered in the face of failure and achieved successDaniel Levangie, CEO of CereVasc, delivered a keynote address to the graduates of Northeastern University’s Bouvé College of Health Sciences on May 6, 2025. During his speech, he recounted his career journey, highlighting his pivotal role at Cytyc Health Corp. where he helped transition cervical cancer screening standards despite initial market resistance. Levangie used this experience to advise students on perseverance and embracing failure as part of professional growth.GlobeNewswireEquityOutlook.Com Announces Stock Ratings: New Ratings on Manugistics Group, Cytyc Corp, E*TRADE Group, McDonald's Corporation, Symantec CorporationEquityOutlook.Com issued new stock ratings on Manugistics, Cytyc, E*TRADE, McDonald's, and Symantec, assigning Outperform or Underperform labels. The ratings are based on a proprietary technical analysis system that assesses short-term price movement versus the S&P 500, not long-term views.GlobeNewswireEquityOutlook.Com Announces Stock Ratings: New Ratings on Manugistics Group, Cytyc Corp, E*TRADE Group, McDonald's Corporation, Symantec CorporationEquityOutlook.Com issued new stock ratings on Manugistics, Cytyc, E*TRADE, McDonald's, and Symantec, assigning Underperform, Outperform, or Underperform labels. The ratings are based on a proprietary technical analysis system that assesses short-term price movement versus the S&P 500, not long-term views.GlobeNewswireEquityOutlook.Com Announces Stock Ratings: New Ratings on Manugistics Group, CYTYC Corp, E*TRADE Group , McDonald's Corporation, Symantec CorporationEquityOutlook.Com issued short-term price ratings on Manugistics, CYTYC, E*TRADE, McDonald's, and Symantec, assigning Outperform to four and Underperform to McDonald's. The company states its proprietary technical analysis system does not indicate a long-term view and advises short-term trading.GlobeNewswireEquityOutlook.Com Announces Stock Ratings: New Ratings on Manugistics Group, Cytyc Corp, E*TRADE Group, McDonald's Corporation, Symantec CorporationEquityOutlook.Com issued new stock ratings on Manugistics, Cytyc, E*TRADE, McDonald's, and Symantec, assigning Outperform or Underperform labels. The ratings are based on a proprietary technical analysis system that assesses short-term price movement versus the S&P 500, not long-term views.